GlassScriptPhysician profile
Robin L Womack
NPI 1750370821
$5,009.04
in general payments reported to CMS, 2019-2025
37 companies · $561 in 2025
The $561 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $73.04 · 2021: $341 · 2022: $812 · 2023: $960 · 2024: $1,830 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Travel and Lodging: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.65 |
| Travel and Lodging | $838.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,232.52 | 2024-2025 | Solyx Sis System |
| Abbvie INC. | $576.20 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $365.59 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $364.17 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $319.11 | 2022-2025 | |
| Astellas Pharma US INC | $283.46 | 2019-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $263.91 | 2021-2025 | Aptima |
| Daiichi Sankyo INC. | $235.26 | 2019-2024 | Injectafer |
| Agile Therapeutics, INC. | $149.20 | 2021-2022 | |
| Pfizer INC. | $84.26 | 2019-2023 | |
| Myriad Women'S Health, INC. | $79.33 | 2023 | Myrisk |
| Organon LLC | $70.96 | 2022-2025 | Nexplanon |
| Biogen, INC. | $70.13 | 2024-2025 | Zurzuvae |
| Ethicon US, LLC | $67.26 | 2021-2022 | |
| Myovant Sciences INC. | $66.38 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $65.29 | 2024 | Photonsaber Y |
| Evofem Biosciences, INC. | $60.88 | 2022-2023 | Phexxi |
| Shield Therapeutics INC | $57.99 | 2023-2024 | Accrufer |
| Coopersurgical, INC. | $52.34 | 2019-2024 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $48.67 | 2022-2024 | Gardasil, Gardasil 9 |
| Innovation Technologies INC | $44.26 | 2024 | Irrisept |
| Amgen INC. | $41.16 | 2019 | |
| Duchesnay USA Incorporated | $40.26 | 2019 | |
| Davol INC. | $39.41 | 2023-2025 | Arista Ah Flexitip, Arista |
| Millicent US INC | $38.90 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Scynexis, INC. | $36.27 | 2022 | |
| Becton, Dickinson and Company | $31.94 | 2025 | Arista |
| Mylan Pharmaceuticals INC. | $31.50 | 2019-2021 | |
| Lupin INC. | $25.69 | 2019-2020 | |
| Therapeuticsmd, INC. | $25.55 | 2022 | |
| Avion Pharmaceuticals | $25.53 | 2020-2023 | Balcoltra |
| Meditrina | $24.53 | 2023-2025 | |
| Minerva Surgical, INC | $24.28 | 2019 | |
| Novo Nordisk INC | $18.74 | 2023 | Wegovy |
| Avanos Medical | $18.05 | 2019 | |
| Convatec INC. | $16.77 | 2023 | |
| Lsi Solutions INC | $13.29 | 2024 | Fornisee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.